Familial aggregation of Hodgkin lymphoma and related tumors§

Authors


  • This article is a U.S. Government work and, as such, is in the public domain in the United States of America.

  • The Swedish Family-Cancer Database was created by linking registers maintained at Statistics Sweden and the Swedish Cancer Registry.

  • §

    The opinions expressed herein do not necessarily reflect the views of the National Cancer Institute or the U.S. Government.

Abstract

BACKGROUND

The importance of genetic factors in the etiology of Hodgkin lymphoma (HL) has been suggested by family and population studies. However, the spectrum of malignancies associated with common genetic etiology and the effects of gender and age on familial risk have not been established.

METHODS

Diagnoses of lymphoproliferative malignancies were compared in 15,799 first-degree relatives of 5047 patients with HL versus 32,117 first-degree relatives of 10,078 control probands from Sweden and in 7185 first-degree relatives of 2429 patients with HL versus 27,434 first-degree relatives of 8,495 control probands from Denmark using marginal survival models.

RESULTS

The risk of HL in relatives of patients with HL was increased significantly in both populations, with relative risks of 3.47 (95% confidence interval [95% CI], 1.77–6.80) in Sweden and 2.55 (95% CI, 1.01–6.45) in Denmark and a pooled estimate of 3.11 (95%CI, 1.82–5.29). In Sweden, risks for relatives of patients also were increased significantly for chronic lymphocytic leukemia and non-Hodgkin lymphoma (in males). Relative risks were higher in males compared with females and in siblings of patients compared with parents and offspring of patients. Relatives of patients with earlier-onset disease were at higher risk for HL.

CONCLUSIONS

HL has an important familial component, which is stronger in families of affected individuals age < 40 years, in males, and in siblings, and it is shared with some (but not other) lymphoproliferative malignancies. The cumulative lifetime risks are very small, however, for the development of HL de novo or in first-degree relatives of affected patients. Cancer 2004. Published 2004 by the American Cancer Society.

Ancillary